Department Of Infectious Diseases 2

51. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
52. A comprehensive health effects assessment of the use of sanitizers and disinfectants during COVID-19 pandemic: a global survey
53. Transmission dynamics and stability analysis of fractional HIV and AIDS epidemic model with antiretroviral therapy
54. A second update on mapping the human genetic architecture of COVID-19
55. A second update on mapping the human genetic architecture of COVID-19
56. A second update on mapping the human genetic architecture of COVID-19
57. A second update on mapping the human genetic architecture of COVID-19
58. Pressure Ulcers and Nutrients: From Established Evidence to Gaps in Knowledge
59. Worldwide Prevalence of Alcohol Use in Non-Fatally Injured Motor Vehicle Drivers: A Systematic Review and Meta-Analysis
60. Evaluation of National Immunization Technical Advisory Groups (NITAGs) of middle-income countries in the WHO European Region; a synopsis
61. Impact of Social Determinants of Health on the Incidence of Tuberculosis in Central Asia
62. Kazakhstani Drivers and Substance Abuse During COVID-19: A Study of Patterns and Disaster Readiness
63. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
64. CLINICAL AND LABORATORY PREDICTORS OF ADVERSE OUTCOME WITH SEVERE COVID-19 IN COMORBID PATIENTS OF THE KARAGANDA REGION (REPUBLIC OF KAZAKHSTAN)
65. The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990–2021: a cross-country systematic analysis with forecasts to 2050
66. Insight into pathogenomics and phylogeography of hypervirulent and highly-lethal Mycobacterium tuberculosis strain cluster
67. Associations of Amino Acids with the Risk of Prediabetes: A Case-Control Study from Kazakhstan
68. Exploring the Link Between Vitamin B Levels and Metabolic Syndrome Risk: Insights from a Case-Control Study in Kazakhstan
69. Nonpharmaceutical interventions reduce the incidence and mortality of COVID-19: A study based on the survey from the International COVID-19 Research Network (ICRN)
70. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
71. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
72. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
73. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
74. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
75. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
76. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
77. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
78. The case for simplifying and using absolute targets for viral hepatitis elimination goals
79. The case for simplifying and using absolute targets for viral hepatitis elimination goals
80. Global health at crossroads: uniting together to overcome challenges, restore trust and advance priorities for a sustainable future
81. Global health at crossroads: uniting together to overcome challenges, restore trust and advance priorities for a sustainable future
82. Global health at crossroads: uniting together to overcome challenges, restore trust and advance priorities for a sustainable future
83. Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia
84. Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia
85. Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia
86. Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia
87. Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia
88. Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia
89. Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia
90. Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia
91. Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia
92. Social Determinants of Health and Antibiotic Consumption
93. Sex differences in risk factors for unsuccessful tuberculosis treatment outcomes in Eastern Europe from 2020 to 2022: a multi-country retrospective cohort study
94. Real-time PCR assay for robust detection and global surveillance of the Mycobacterium tuberculosis Haarlem genotype
95. Influence of endometriosis on mammary glands’ pathology induced by different factors: a pilot study in the republic of Kazakhstan
96. Bibliometric Analysis of Alpha-Synuclein Determination by Biopsy in Peripheral Tissues of Patients With Parkinson’s Disease
97. The prevalence and risk factors of pressure ulcers among residents of long-term care institutions: a case study of Kazakhstan
98. World Tuberculosis Day 2021 Theme — ‘The Clock is Ticking’ — and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic
1 2 2